Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Other Accumulated Expenses (2023 - 2025)

Historic Other Accumulated Expenses for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $580000.0.

  • Zenas BioPharma's Other Accumulated Expenses rose 7469.88% to $580000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $580000.0, marking a year-over-year increase of 7469.88%. This contributed to the annual value of $249000.0 for FY2024, which is 13490.57% up from last year.
  • As of Q3 2025, Zenas BioPharma's Other Accumulated Expenses stood at $580000.0, which was up 7469.88% from $508000.0 recorded in Q2 2025.
  • Zenas BioPharma's Other Accumulated Expenses' 5-year high stood at $580000.0 during Q3 2025, with a 5-year trough of $106000.0 in Q4 2023.
  • Its 3-year average for Other Accumulated Expenses is $359833.3, with a median of $358000.0 in 2024.
  • In the last 5 years, Zenas BioPharma's Other Accumulated Expenses surged by 13490.57% in 2024 and then soared by 7469.88% in 2025.
  • Quarter analysis of 3 years shows Zenas BioPharma's Other Accumulated Expenses stood at $106000.0 in 2023, then surged by 134.91% to $249000.0 in 2024, then soared by 132.93% to $580000.0 in 2025.
  • Its last three reported values are $580000.0 in Q3 2025, $508000.0 for Q2 2025, and $384000.0 during Q1 2025.